Isoquercetin
CAS 482-35-9
Isoquercetin (CAS 482-35-9) is a Phase 2 pharmaceutical compound with 9 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 31704.01963636364 nM | 53 | - |
| - | MIC | 767.75 ug.mL-1 | 16 | - |
| - | Ki | 8265.709090909091 nM | 11 | - |
| - | IC50 | 13.577777777777778 ug.mL-1 | 9 | - |
| - | Potency | 10434.900000000001 nM | 9 | - |
| - | MIC | 89766.66666666667 nM | 3 | - |
| - | EC50 | 47000.67 nM | 2 | - |
| - | EC50 | 20.4 ug.mL-1 | 1 | - |
| - | IC50 | 570 molar ratio | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Isoquercetin used for in pharmaceutical contexts?
Isoquercetin (CAS 482-35-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Isoquercetin?
No adverse-event association or SIDER side-effect rows are rendered for Isoquercetin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Isoquercetin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Isoquercetin with EU status "permitted".
What clinical phase is Isoquercetin in?
Isoquercetin is rendered with ChEMBL max phase 2.